Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 649 entries
Sorted by: Best Match Show Resources per page
Association between learning environment interventions and medical student well-being: a systematic review

education interventions

Meli L, Falzon L.
GSID: nOMUTl1fm5QJ
LT Wasson, A Cusmano, L Meli, I Louh, L Falzon… - Jama, 2016 - jamanetwork.com

… The MERSQI was preferred to the Newcastle-Ottawa Scale–Education (NOS-E), another assessment tool for medical education research quality, because it was found to have generally higher interrater reliability (0.68-0.89) 11 than the NOS-E. This may be due to its...

Cite
Wasson, L. T., Cusmano, A., Meli, L., Louh, I., Falzon, L., Hampsey, M., ... & Davidson, K. W. (2016). Association between learning environment interventions and medical student well-being: a systematic review. Jama, 316(21), 2237-2252.
Wasson, Lauren T., et al. "Association between learning environment interventions and medical student well-being: a systematic review." Jama 316.21 (2016): 2237-2252.
Copy Download .nbib Format: MLA
Commentary: A BK (Slo1) channel journey from molecule to physiology.

Frontiers in pharmacology

Tricarico D, Mele A.
PMID: 28424624
Front Pharmacol. 2017 Apr 05;8:188. doi: 10.3389/fphar.2017.00188. eCollection 2017.

No abstract available.

Cite
Tricarico D, Mele A. Commentary: A BK (Slo1) channel journey from molecule to physiology. Front Pharmacol. 2017;8:188doi: 10.3389/fphar.2017.00188.
Tricarico, D., & Mele, A. (2017). Commentary: A BK (Slo1) channel journey from molecule to physiology. Frontiers in pharmacology, 8188. https://doi.org/10.3389/fphar.2017.00188
Tricarico, Domenico, and Mele, Antonietta. "Commentary: A BK (Slo1) channel journey from molecule to physiology." Frontiers in pharmacology vol. 8 (2017): 188. doi: https://doi.org/10.3389/fphar.2017.00188
Tricarico D, Mele A. Commentary: A BK (Slo1) channel journey from molecule to physiology. Front Pharmacol. 2017 Apr 05;8:188. doi: 10.3389/fphar.2017.00188. eCollection 2017. PMID: 28424624; PMCID: PMC5380717.
Copy Download .nbib Format: NLM
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Frontiers in pharmacology

Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D.
PMID: 27242528
Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016.

In the human genome more than 400 genes encode ion channels, which are transmembrane proteins mediating ion fluxes across membranes. Being expressed in all cell types, they are involved in almost all physiological processes, including sense perception, neurotransmission, muscle...

Cite
Imbrici P, Liantonio A, Camerino GM, et al. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016;7:121doi: 10.3389/fphar.2016.00121.
Imbrici, P., Liantonio, A., Camerino, G. M., De Bellis, M., Camerino, C., Mele, A., Giustino, A., Pierno, S., De Luca, A., Tricarico, D., Desaphy, J. F., & Conte, D. (2016). Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Frontiers in pharmacology, 7121. https://doi.org/10.3389/fphar.2016.00121
Imbrici, Paola, et al. "Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery." Frontiers in pharmacology vol. 7 (2016): 121. doi: https://doi.org/10.3389/fphar.2016.00121
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. PMID: 27242528; PMCID: PMC4861771.
Copy Download .nbib Format: NLM
Notch Signaling in Neuroendocrine Tumors.

Frontiers in oncology

Crabtree JS, Singleton CS, Miele L.
PMID: 27148486
Front Oncol. 2016 Apr 14;6:94. doi: 10.3389/fonc.2016.00094. eCollection 2016.

Carcinoids and neuroendocrine tumors (NETs) are a heterogeneous group of tumors that arise from the neuroendocrine cells of the GI tract, endocrine pancreas, and the respiratory system. NETs remain significantly understudied with respect to molecular mechanisms of pathogenesis, particularly...

Cite
Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine Tumors. Front Oncol. 2016;6:94doi: 10.3389/fonc.2016.00094.
Crabtree, J. S., Singleton, C. S., & Miele, L. (2016). Notch Signaling in Neuroendocrine Tumors. Frontiers in oncology, 694. https://doi.org/10.3389/fonc.2016.00094
Crabtree, Judy S, et al. "Notch Signaling in Neuroendocrine Tumors." Frontiers in oncology vol. 6 (2016): 94. doi: https://doi.org/10.3389/fonc.2016.00094
Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine Tumors. Front Oncol. 2016 Apr 14;6:94. doi: 10.3389/fonc.2016.00094. eCollection 2016. PMID: 27148486; PMCID: PMC4830836.
Copy Download .nbib Format: NLM
The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver.

Clinica chimica acta; international journal of clinical chemistry

Zhou YJ, Zheng JN, Liu WY, Miele L, Vitale A, Van Poucke S, Zou TT, Fang DH, Shen S, Zhang DC, Zheng MH.
PMID: 28111272
Clin Chim Acta. 2017 May;468:17-24. doi: 10.1016/j.cca.2017.01.021. Epub 2017 Jan 19.

BACKGROUND: Although several risk factors for non-alcoholic fatty liver (NAFL) have been reported, there are few clinical scores that predict its incidence in the long term. We developed and validate a scoring model for individual prediction of 4-y risk...

Cite
Zhou YJ, Zheng JN, Liu WY, et al. The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. Clin Chim Acta. 2017;468:17-24doi: 10.1016/j.cca.2017.01.021.
Zhou, Y. J., Zheng, J. N., Liu, W. Y., Miele, L., Vitale, A., Van Poucke, S., Zou, T. T., Fang, D. H., Shen, S., Zhang, D. C., & Zheng, M. H. (2017). The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. Clinica chimica acta; international journal of clinical chemistry, 46817-24. https://doi.org/10.1016/j.cca.2017.01.021
Zhou, Yu-Jie, et al. "The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver." Clinica chimica acta; international journal of clinical chemistry vol. 468 (2017): 17-24. doi: https://doi.org/10.1016/j.cca.2017.01.021
Zhou YJ, Zheng JN, Liu WY, Miele L, Vitale A, Van Poucke S, Zou TT, Fang DH, Shen S, Zhang DC, Zheng MH. The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. Clin Chim Acta. 2017 May;468:17-24. doi: 10.1016/j.cca.2017.01.021. Epub 2017 Jan 19. PMID: 28111272.
Copy Download .nbib Format: NLM
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study.

ERJ open research

Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP.
PMID: 27730152
ERJ Open Res. 2015 Oct 19;1(2). doi: 10.1183/23120541.00029-2015. eCollection 2015 Oct.

Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing.

Cite
Berghmans T, Lafitte JJ, Scherpereel A, et al. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Res. 2015;1(2)doi: 10.1183/23120541.00029-2015.
Berghmans, T., Lafitte, J. J., Scherpereel, A., Ameye, L., Paesmans, M., Meert, A. P., Colinet, B., Tulippe, C., Willems, L., Leclercq, N., Sculier, J. P. (2015). VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ open research, 1(2), . https://doi.org/10.1183/23120541.00029-2015
Berghmans, Thierry, et al. "VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study." ERJ open research vol. 1,2 (2015). doi: https://doi.org/10.1183/23120541.00029-2015
Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP. VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Res. 2015 Oct 19;1(2). doi: 10.1183/23120541.00029-2015. eCollection 2015 Oct. PMID: 27730152; PMCID: PMC5005117.
Copy Download .nbib Format: NLM
Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis.

PloS one

Corrado A, Colia R, Mele A, Di Bello V, Trotta A, Neve A, Cantatore FP.
PMID: 26545109
PLoS One. 2015 Nov 06;10(11):e0142748. doi: 10.1371/journal.pone.0142748. eCollection 2015.

No abstract available.

Cite
Corrado A, Colia R, Mele A, et al. Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis. PLoS One. 2015;10(11):e0142748doi: 10.1371/journal.pone.0142748.
Corrado, A., Colia, R., Mele, A., Di Bello, V., Trotta, A., Neve, A., & Cantatore, F. P. (2015). Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis. PloS one, 10(11), e0142748. https://doi.org/10.1371/journal.pone.0142748
Corrado, Addolorata, et al. "Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis." PloS one vol. 10,11 (2015): e0142748. doi: https://doi.org/10.1371/journal.pone.0142748
Corrado A, Colia R, Mele A, Di Bello V, Trotta A, Neve A, Cantatore FP. Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis. PLoS One. 2015 Nov 06;10(11):e0142748. doi: 10.1371/journal.pone.0142748. eCollection 2015. PMID: 26545109; PMCID: PMC4636383.
Copy Download .nbib Format: NLM
Geospatial cryptography: enabling researchers to access private, spatially referenced, human subjects data for cancer control and prevention.

Journal of geographical systems

Jacquez GM, Essex A, Curtis A, Kohler B, Sherman R, Emam KE, Shi C, Kaufmann A, Beale L, Cusick T, Goldberg D, Goovaerts P.
PMID: 29085255
J Geogr Syst. 2017 Jul;19(3):197-220. doi: 10.1007/s10109-017-0252-3. Epub 2017 May 11.

As the volume, accuracy and precision of digital geographic information have increased, concerns regarding individual privacy and confidentiality have come to the forefront. Not only do these challenge a basic tenet underlying the advancement of science by posing substantial...

Cite
Jacquez GM, Essex A, Curtis A, et al. Geospatial cryptography: enabling researchers to access private, spatially referenced, human subjects data for cancer control and prevention. J Geogr Syst. 2017;19(3):197-220doi: 10.1007/s10109-017-0252-3.
Jacquez, G. M., Essex, A., Curtis, A., Kohler, B., Sherman, R., Emam, K. E., Shi, C., Kaufmann, A., Beale, L., Cusick, T., Goldberg, D., & Goovaerts, P. (2017). Geospatial cryptography: enabling researchers to access private, spatially referenced, human subjects data for cancer control and prevention. Journal of geographical systems, 19(3), 197-220. https://doi.org/10.1007/s10109-017-0252-3
Jacquez, Geoffrey M, et al. "Geospatial cryptography: enabling researchers to access private, spatially referenced, human subjects data for cancer control and prevention." Journal of geographical systems vol. 19,3 (2017): 197-220. doi: https://doi.org/10.1007/s10109-017-0252-3
Jacquez GM, Essex A, Curtis A, Kohler B, Sherman R, Emam KE, Shi C, Kaufmann A, Beale L, Cusick T, Goldberg D, Goovaerts P. Geospatial cryptography: enabling researchers to access private, spatially referenced, human subjects data for cancer control and prevention. J Geogr Syst. 2017 Jul;19(3):197-220. doi: 10.1007/s10109-017-0252-3. Epub 2017 May 11. PMID: 29085255; PMCID: PMC5659297.
Copy Download .nbib Format: NLM
Evaluating the impact of a resident research program in general surgery.

Canadian medical education journal

Allen L, Vogt K, Mele T, Ott M, Leslie K, Colquhoun P.
PMID: 29098044
Can Med Educ J. 2017 Jun 30;8(3):e13-e20. eCollection 2017 Jun.

BACKGROUND: Programs of resident research have been found to improve research productivity. However, evidence of the success of these programs is lacking in a Canadian context. The objective of this study was to evaluate the impact of the introduction...

Cite
Allen L, Vogt K, Mele T, et al. Evaluating the impact of a resident research program in general surgery. Can Med Educ J. 2017;8(3):e13-e20
Allen, L., Vogt, K., Mele, T., Ott, M., Leslie, K., & Colquhoun, P. (2017). Evaluating the impact of a resident research program in general surgery. Canadian medical education journal, 8(3), e13-e20.
Allen, Laura, et al. "Evaluating the impact of a resident research program in general surgery." Canadian medical education journal vol. 8,3 (2017): e13-e20.
Allen L, Vogt K, Mele T, Ott M, Leslie K, Colquhoun P. Evaluating the impact of a resident research program in general surgery. Can Med Educ J. 2017 Jun 30;8(3):e13-e20. eCollection 2017 Jun. PMID: 29098044; PMCID: PMC5661734.
Copy Download .nbib Format: NLM
Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

PloS one

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.
PMID: 28582423
PLoS One. 2017 Jun 05;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017.

[This corrects the article DOI: 10.1371/journal.pone.0175207.].

Cite
Moots RJ, Xavier RM, Mok CC, et al. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(6):e0179308doi: 10.1371/journal.pone.0179308.
Moots, R. J., Xavier, R. M., Mok, C. C., Rahman, M. U., Tsai, W. C., Al-Maini, M. H., Pavelka, K., Mahgoub, E., Kotak, S., Korth-Bradley, J., Pedersen, R., Mele, L., Shen, Q., & Vlahos, B. (2017). Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PloS one, 12(6), e0179308. https://doi.org/10.1371/journal.pone.0179308
Moots, Robert J, et al. "Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study." PloS one vol. 12,6 (2017): e0179308. doi: https://doi.org/10.1371/journal.pone.0179308
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Jun 05;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017. PMID: 28582423; PMCID: PMC5459555.
Copy Download .nbib Format: NLM
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Blood cancer journal

Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P.
PMID: 24270324
Blood Cancer J. 2013 Nov 22;3:e162. doi: 10.1038/bcj.2013.58.

Bendamustine demonstrated synergistic efficacy with bortezomib against multiple myeloma (MM) cells in vitro and seems an effective treatment for relapsed-refractory MM (rrMM). This phase II study evaluated bendamustine plus bortezomib and dexamethasone (BVD) administered over six 28-day cycles and...

Cite
Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3:e162doi: 10.1038/bcj.2013.58.
Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti, A., Cellini, C., Malerba, L., Mele, A., Andriani, A., Galimberti, S., Mondello, P., Pulini, S., Coppetelli, U., Fraticelli, P., Olivieri, A., & Leoni, P. (2013). Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood cancer journal, 3e162. https://doi.org/10.1038/bcj.2013.58
Offidani, M, et al. "Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study." Blood cancer journal vol. 3 (2013): e162. doi: https://doi.org/10.1038/bcj.2013.58
Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013 Nov 22;3:e162. doi: 10.1038/bcj.2013.58. PMID: 24270324; PMCID: PMC3880441.
Copy Download .nbib Format: NLM
Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

BoneKEy reports

Boskey AL.
PMID: 26069736
Bonekey Rep. 2015 Jun 03;4:710. doi: 10.1038/bonekey.2015.79. eCollection 2015.

[This corrects the article DOI: 10.1038/bonekey.2013.181.].

Cite
Boskey AL. Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects. Bonekey Rep. 2015;4:710doi: 10.1038/bonekey.2015.79.
Boskey, A. L. (2015). Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects. BoneKEy reports, 4710. https://doi.org/10.1038/bonekey.2015.79
Boskey, Adele L. "Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects." BoneKEy reports vol. 4 (2015): 710. doi: https://doi.org/10.1038/bonekey.2015.79
Boskey AL. Erratum: Bone composition: relationship to bone fragility and antiosteoporotic drug effects. Bonekey Rep. 2015 Jun 03;4:710. doi: 10.1038/bonekey.2015.79. eCollection 2015. PMID: 26069736; PMCID: PMC4455689.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 649 entries